TELO logo

TELOMIR PHARMACEUTICALS INC

TELONASDAQ
🏆 #4197 by market capEarnings Nov 9US Equity
$1.18▼ $0.02 (−1.67%)
Pre-market · at close
🔔
Track TELO
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 1.7%
7d▼ 5.6%
14d▲ 1.7%
30d▲ 4.9%
ytd▼ 11.3%
1y▼ 15.1%
🏦Market Cap
$81M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$1.17 – $1.19
52-Week Range
$0.89 – $2.09
Volume
$3.84B
Avg Volume
$2.68B
Shares Outstanding
68.8M
Next Earnings
Oct 29, 2026

Fundamentals Snapshot

Annual Revenue
$8M
Last Q Revenue
$2M
P/E Ratio
-0.8
P/S Ratio
0.0x
EPS (TTM)
$-0.17
Dividend Yield
0.00%
Dilution (1yr)
+16.4%

Why Investors Own TELO

  • ✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 73% gross margin and 29% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

TELO logo

TELOMIR PHARMACEUTICALS INC

TELO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$11M▼ −13.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$4M▼ −27.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
34.4M▲ +16.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$7M▲ +$6M YoY
StockOtter · stockotter.space

About TELOMIR PHARMACEUTICALS INC

Telomir Pharmaceuticals, Inc. operates as a preclinical-stage pharmaceutical firm, concentrating its efforts on creating and launching novel therapeutic interventions. Its primary focus involves the development of TELOMIR-1, an innovative small molecule compound. This oral medication is being engineered to serve as a therapeutic solution against various age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, and also to assist in recovery post-chemotherapy. It achieves this by disrupting and inhibiting inflammatory pathways that are triggered by interleukin-17. Established in 2021, the company was initially known as Metallo Therapies Inc., officially adopting the name Telomir Pharmaceuticals, Inc. on October 10, 2022. The company's headquarters are located in Baltimore, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$1.27
▲ +8.0% Upside
High Target$1.57
Low Target$1.18
Based on 41 analysts

Latest News & Updates

🚀
Barron’s·2h ago

TELOMIR PHARMACEUTICALS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift TELO price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

TELOMIR PHARMACEUTICALS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.